Lipocine and verity pharma enter into license agreement for tlando® franchise in the u.s. and canada

Lipocine to receive $11 million license fee up to $259 million in development and commercial sales milestones tiered royalties on net sales of licensed products up to 18% commercialization of tlando transitions to verity pharma effective feb.1 2024 lipocine retains all rights for territories outside the united states and canada, and all non-trt rights globally salt lake city , jan. 18, 2024 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company focused on treating central nervous system (cns) disorders, gordon silver limited and verity pharmaceuticals, inc. (verity pharma) today announced that they have entered into an exclusive licensing agreement under which verity pharma will market tlando® in the united states and, if approved, in canada.  tlando is the first and only oral testosterone replacement therapy (trt) option approved by the us food and drug administration (fda) that does not require dose titration.
LPCN Ratings Summary
LPCN Quant Ranking